Carbonic anhydrase 9 (CA IX) (CA IX)

Carbonic anhydrase 9 (CA IX) is a transmembrane zinc-metalloprotein that belongs to the alpha-carbonic anhydrase family (UniProt: Q16790). It is uniquely characterized by its high expression in various solid tumors, particularly under hypoxic conditions, while remaining largely absent in most normal tissues (NCBI Gene: 768). CA IX plays a critical role in the tumor microenvironment by catalyzing the reversible hydration of carbon dioxide into bicarbonate and protons (PubMed: 25103141). This enzymatic activity facilitates extracellular acidification and maintains an alkaline intracellular pH, which is essential for tumor cell survival in harsh conditions. This pH gradient promotes tumor cell migration, invasion, and resistance to certain chemotherapies, making CA IX a significant driver of cancer progression and metastasis (PubMed: 23479538). In clinical practice, CA IX is a well-established biomarker for clear cell renal cell carcinoma and other hypoxic malignancies. Therapeutically, CA IX is targeted using small-molecule inhibitors, such as the sulfonamide SLC-0111, which is currently in clinical trials (PubMed: 30217958). Additionally, monoclonal antibodies like Girentuximab are used for both diagnostic imaging and targeted therapy, including radioimmunotherapy.

Other names

CA-IXCA9Carbonate dehydratase IXG250MNRenal cell carcinoma-associated antigen G250

CA IX inhibitors primarily act by binding to the zinc ion in the enzyme's active site, preventing the hydration of carbon dioxide and thus inhibiting the acidification of the extracellular tumor environment (PubMed: 25103141). Monoclonal antibodies target the extracellular domain of CA IX to induce antibody-dependent cellular cytotoxicity (ADCC) or deliver radioisotopes for imaging and therapy (PubMed: 23479538).